Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Paraneoplastic glomerulopathies

S H Norris1

  • 1Department of Internal Medicine, Texas Tech University School of Medicine, Lubbock 79430.

Seminars in Nephrology
|May 1, 1993
PubMed
Summary
This summary is machine-generated.

Cancer patients often develop immune complexes that can damage kidneys, leading to paraneoplastic glomerulopathy. Early cancer detection may improve outcomes for these patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety, pharmacokinetics and biological activity of enlimomab (anti-ICAM-1 antibody): an open-label, dose escalation study in patients hospitalized for acute stroke.

European neurology·1998
Same author

A phase I/II open label study of the safety and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis.

The Journal of rheumatology·1996
Same author

First carpometacarpal joint arthritis. A comparison of two arthroplasty techniques.

Journal of hand surgery (Edinburgh, Scotland)·1996
Same author

Quiz of the month.

American journal of nephrology·1995
Same author

Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1.

Arthritis and rheumatism·1994
Same author

Isotype choice for chimeric antibodies affects binding properties.

The Journal of biological chemistry·1994
Same journal

Current Options for Kidney Protection: Are Renin-Angiotensin System Inhibitors Still Relevant?

Seminars in nephrology·2026
Same journal

Proposed Role for Quantitative Podocyturia as a Clinical Marker of Systemic Endothelial Injury: Implications for Cardiovascular Disease and Longevity.

Seminars in nephrology·2026
Same journal

Kidney Protection Options in 2025: Are Renin-Angiotensin System Inhibitors Still Needed?

Seminars in nephrology·2026
Same journal

From Nephron Number to Global Health.

Seminars in nephrology·2026
Same journal

Chronic Kidney Disease Progression Mechanisms: Why They Matter in an Era of Novel Kidney Protective Therapies.

Seminars in nephrology·2026
Same journal

Of Diuretics, Transporters, and Mechanisms of Hypertension.

Seminars in nephrology·2026
See all related articles

Area of Science:

  • Nephrology
  • Oncology
  • Immunology

Background:

  • Neoplastic diseases expose patients to continuous antigenemia, stimulating antibody production and immune complex formation.
  • These immune reactants can deposit in the glomeruli, leading to kidney damage.
  • Proteinuria in cancer patients indicates a worse prognosis.

Purpose of the Study:

  • To investigate the link between cancer and paraneoplastic glomerulopathy.
  • To understand the clinical manifestations and prognosis of cancer-associated kidney disease.

Main Methods:

  • Review of existing literature on cancer and renal disease.
  • Analysis of clinical data from cancer patients with glomerular injury.

Main Results:

Related Experiment Videos

  • Up to 80% of cancer patients experience antigenemia, potentially leading to immune complex deposition.
  • Less than 1% of adult cancer patients develop overt paraneoplastic renal disease, most commonly Minimal Change Glomerulopathy (MCG).
  • Successful cancer treatment can lead to remission of associated glomerulopathy, but overall prognosis remains poor.

Conclusions:

  • Paraneoplastic glomerulopathy is a rare but serious complication of cancer.
  • Early recognition and treatment of the underlying malignancy are crucial for managing associated kidney disease.
  • Consideration of cancer screening in older patients with unexplained nephrotic syndrome is warranted.